[90Y]Y-ibritumomab

Compound class

Radiolabeled anti-CD20 monoclonal antibody (ibritumomab tiuxetan)

Target / mechanism

Binds CD20 antigen on B cells PMID 31546999

Clinical application

CD20-targeted radioimmunotherapy for B-cell non-Hodgkin lymphoma PMID 36775698

Theranostic pair

—

FDA

Yes — 2002; Zevalin (ibritumomab tiuxetan); sponsor SPECTRUM PHARMS; BLA 125019; marketing status 'Prescription' Drugs@FDA / openFDA drug registry, BLA 125019, original approval 2002-02-19 — https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125019%22 (queried 2026-09-18)

EMA (centralised)

Lapsed — 2004; Zevalin (ibritumomab tiuxetan); Ceft Biopharma s.r.o.; EMEA/H/C/000547; authorised 2004-01-16, register status 'Lapsed' (lapse date 2024-01-04) EMA medicines register (JSON export 2026-09-18), EPAR Zevalin: medicine status 'Lapsed', marketing authorisation date 2004-01-16, withdrawal/expiry/revocation/lapse date 2024-01-04 — https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin

Other approvals

Canada: ZEVALIN, DIN 02328674, Auro Pharma Inc.; Health Canada status 'Approved' (status date 2023-12-06; original market date 2018-09-12)

Brand names

—

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

1. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
   2014 · Haematologica · Prospective, multicentre · Phase II
2. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
   2002 · Blood · Multicentre · Phase II
3. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
   2001 · Crit Rev Oncol Hematol · Prospective, multicentre · Phase III
4. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
   1999 · J Clin Oncol · Multicentre · Phase I/II
5. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
   2011 · Cancer · Prospective
6. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
   2009 · Neuro Oncol · Prospective · Phase II
7. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.
   2007 · Cancer · Prospective
8. Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar.
   2019 · Pharmaceuticals (Basel) · Retrospective
9. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma.
   2010 · Eur J Nucl Med Mol Imaging · Retrospective
10. 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma.
    2010 · Mol Imaging Biol · Retrospective